featured
Pembrolizumab vs Investigator-Choice Chemotherapy for Ipilimumab-Refractory Melanoma (KEYNOTE-002)
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Pembrolizumab vs Investigator-Choice Chemotherapy for Ipilimumab-Refractory Melanoma (KEYNOTE-002): A Randomized, Controlled, Phase 2 Trial
Lancet Oncol 2015 Jun 23;[EPub Ahead of Print], A Ribas, I Puzanov, R Dummer, D Schadendorf, O Hamid, C Robert, FS Hodi, J Schachter, AC Pavlick, KD Lewis, LD Cranmer, CU Blank, SJ O'Day, PA Ascierto, AK Salama, KA Margolin, C Loquai, TK Eigentler, TC Gangadhar, MS Carlino, SS Agarwala, SJ Moschos, JA Sosman, SM Goldinger, R Shapira-Frommer, R Gonzalez, JM Kirkwood, JD Wolchok, A Eggermont, XN Li, W Zhou, AM Zernhelt, J Lis, S Ebbinghaus, SP Kang, A DaudFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.